BR0010092A - Compound, pharmaceutical preparation for oral or parenteral administration, use of a compound, and, use of the pharmaceutical preparation - Google Patents

Compound, pharmaceutical preparation for oral or parenteral administration, use of a compound, and, use of the pharmaceutical preparation

Info

Publication number
BR0010092A
BR0010092A BR0010092-7A BR0010092A BR0010092A BR 0010092 A BR0010092 A BR 0010092A BR 0010092 A BR0010092 A BR 0010092A BR 0010092 A BR0010092 A BR 0010092A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical preparation
oral
parenteral administration
pharmaceutical
Prior art date
Application number
BR0010092-7A
Other languages
Portuguese (pt)
Inventor
Johann-Christian Zechel
Andreas Kling
Herve Geneste
Udo Lange
Arnulf Lauterbach
Claudia Isabella Graef
Thomas Subkowski
Wilfried Hornberger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999119218 external-priority patent/DE19919218A1/en
Priority claimed from DE1999148269 external-priority patent/DE19948269A1/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR0010092A publication Critical patent/BR0010092A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

"COMPOSTO, PREPARAçãO FARMACêUTICA PARA A ADMINISTRAçãO ORAL OU PARENTERAL, USO DE UM COMPOSTO, E, USO DA PREPARAçãO FARMACêUTICA". A invenção refere-se a novos compostos que se ligam a receptores de integrina, assim como a sua produção, seu uso com antagonistas de receptor de integrina e para o tratamento de doenças, preparações farmacêutica, contendo ditos compostos e preparações farmacêuticas em pelo menos outro composto ativo."COMPOUND, PHARMACEUTICAL PREPARATION FOR ORAL OR PARENTERAL ADMINISTRATION, USE OF A COMPOUND, AND USE OF PHARMACEUTICAL PREPARATION". The invention relates to new compounds that bind to integrin receptors, as well as their production, their use with integrin receptor antagonists and for the treatment of diseases, pharmaceutical preparations, containing said compounds and pharmaceutical preparations in at least one other active compound.

BR0010092-7A 1999-04-28 2000-04-17 Compound, pharmaceutical preparation for oral or parenteral administration, use of a compound, and, use of the pharmaceutical preparation BR0010092A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999119218 DE19919218A1 (en) 1999-04-28 1999-04-28 New peptide compounds, e.g. aza-heterocyclic substituted beta-alanine derivatives, are integrin receptor antagonists useful e.g. for treating atherosclerosis, cancer, osteoporosis, hypertension or inflammation
DE1999148269 DE19948269A1 (en) 1999-10-06 1999-10-06 New compounds as integrin antagonists useful for treating e.g. cardiovascular disorders, rheumatoid arthritis, kidney failure, stroke, cancer, osteoporosis, psoriasis or infection
PCT/EP2000/003469 WO2000066618A1 (en) 1999-04-28 2000-04-17 Integrin receptor antagonists

Publications (1)

Publication Number Publication Date
BR0010092A true BR0010092A (en) 2002-06-11

Family

ID=26053109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010092-7A BR0010092A (en) 1999-04-28 2000-04-17 Compound, pharmaceutical preparation for oral or parenteral administration, use of a compound, and, use of the pharmaceutical preparation

Country Status (19)

Country Link
EP (1) EP1173468A1 (en)
JP (1) JP2003500339A (en)
KR (1) KR20020010618A (en)
CN (1) CN1355811A (en)
AU (1) AU4551500A (en)
BG (1) BG106040A (en)
BR (1) BR0010092A (en)
CA (1) CA2371604A1 (en)
CZ (1) CZ20013846A3 (en)
HK (1) HK1046692A1 (en)
HU (1) HUP0202898A2 (en)
IL (1) IL146146A0 (en)
MX (1) MXPA01010834A (en)
NO (1) NO20015237L (en)
PL (1) PL352777A1 (en)
RU (1) RU2001132141A (en)
SK (1) SK15342001A3 (en)
TR (1) TR200103090T2 (en)
WO (1) WO2000066618A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10204789A1 (en) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitors of the integrin alpha¶v¶beta6
KR100759130B1 (en) * 2005-02-12 2007-09-19 휴메드 주식회사 Anti-integrin antibody coated stent and preparation method thereof
US8716320B2 (en) * 2006-07-21 2014-05-06 Replidyne, Inc. Antibacteriall heterocyclic ureas
WO2009015193A1 (en) 2007-07-23 2009-01-29 Replidyne, Inc. Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds
US8148380B2 (en) 2007-07-23 2012-04-03 Crestone, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
EA019990B1 (en) * 2009-06-02 2014-07-30 Бёрингер Ингельхайм Интернациональ Гмбх DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
BR112014016736A8 (en) * 2012-01-27 2017-07-04 Hoffmann La Roche compound, pharmaceutical composition, method for treatment, use of a compound and invention
RU2731807C1 (en) * 2020-05-05 2020-09-08 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт ревматологии имени В.А.Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) Method for determining indications to beginning of reception of genetic engineering biological preparations with ineffectiveness of basic anti-inflammatory preparations in early forms of psoriatic arthritis
CN121079081A (en) * 2023-04-21 2025-12-05 图宾根埃伯哈德卡尔斯大学 Inhibitors of transcription factor HilD

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9610422A (en) * 1995-08-30 1999-07-13 Searle & Co Meta-guanidine derivatives urea thiourea or azacyclic aminobenzoic acid as integrin antagonists
GB2327609A (en) * 1997-07-23 1999-02-03 Merck & Co Inc A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect
EP0928790B1 (en) * 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
CZ20003672A3 (en) * 1998-04-10 2001-08-15 G. D. Searle & Co. Heterocyclic glycyl-beta-alanine derivatives as vitronectin agonists

Also Published As

Publication number Publication date
RU2001132141A (en) 2004-03-20
KR20020010618A (en) 2002-02-04
HK1046692A1 (en) 2003-01-24
JP2003500339A (en) 2003-01-07
SK15342001A3 (en) 2002-06-04
WO2000066618A1 (en) 2000-11-09
CZ20013846A3 (en) 2002-06-12
PL352777A1 (en) 2003-09-08
AU4551500A (en) 2000-11-17
TR200103090T2 (en) 2002-05-21
NO20015237D0 (en) 2001-10-26
IL146146A0 (en) 2002-07-25
BG106040A (en) 2002-05-31
CN1355811A (en) 2002-06-26
NO20015237L (en) 2001-12-21
EP1173468A1 (en) 2002-01-23
MXPA01010834A (en) 2002-04-24
CA2371604A1 (en) 2000-11-09
HUP0202898A2 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
PT1076644E (en) AMINOTETHALINES REPLACED IN EITHER AS LIGANDS FOR THE NEUROPEPTIDEOY Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER PERTURBACES
BR0015188A (en) Pharmaceutical compositions
CO5011096A1 (en) MEDICINES CONTAINING ANTAGONISTS OF THE 5-HT3 RECEPTOR FOR THE TREATMENT OF IBS
PT1119543E (en) N-ARALHYLAMINOTETRALINES AS LIGANDS FOR NEUROPEPTIDE AND Y5 RECEPTOR
ES2091877T3 (en) USE OF ANGIOTENSIN II ANTAGONISTS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HYPERURICEMIA.
BR9712523A (en) New heterocyclyl-substituted pyrazole derivatives
BR9916576A (en) Use of at-1 receptor antagonist or at-2 receptor modulator for the treatment of diseases associated with an increase in at-1 or at-2 receptors
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
BR9812381A (en) Peptopiranosilnucleosìdeo, its preparation and use
BR9712816A (en) Benzamidine derivatives and their use as drugs with an ltb4 antagonistic activity
BR9909486A (en) Calcilic compounds
BR0015322A (en) Derivatives of indene-, naphtha- and benzocyclohepta-dihydrothiazole, their preparation and their use as anoretic drugs
ATE252377T1 (en) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING TILIDINE MESYLATE AS THE ACTIVE INGREDIENT
BR0014826A (en) Bicyclic imidazo-3-yl-amines, their preparation procedure and medications containing them
BR0010092A (en) Compound, pharmaceutical preparation for oral or parenteral administration, use of a compound, and, use of the pharmaceutical preparation
BR0010802A (en) Il-8 receptor antagonists
PT101444A (en) SYNERGIZING ASSOCIATION WITH ANTAGONIST EFFECT OF RECEPTORS NK1 AND NK2, USE OF ANTAGONIST ACTIVITY OF NK1 AND NK2 RECEPTORS IN THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE REFERENCE ASSOCIATION
NO996442L (en) Use of a specific antagonist of 5HT2 receptors for the manufacture of medicaments useful for the treatment of sleep apnea syndrome
BR0211729A (en) Compounds, pharmaceutical compositions, process for manufacturing compounds, use of one or more compounds, and process for manufacturing pharmaceutical compositions
BR0013265A (en) Compound, use of a structural element, drug, pharmaceutical preparation for oral or parenteral use, and use of the compound
BR9814951A (en) Carboxylic acid derivative, use of it, preparation of medication for oral, parenteral use, combination, use of compounds, structural fragment, use of it, endothelin receptor antagonist, and, compound
ATE390124T1 (en) TREATMENT OF MASTITIS WITH A COMBINATION OF PREDNISOLONE AND CEPHALOSPORIN
HUP0203338A2 (en) Integrin receptor ligands
ATE284878T1 (en) PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH & CO. KG (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 7A., 8A. E 9A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.